[ Team ] The people behind the progress

Builders who have done it before.

Our team has extensive experience in creating new ventures, and a broad understanding of every phase of the venture creation process, from first patent to exit.

[ 01 ] Record of success

Inception to exit, many times over.

Between them, our principals have formed, financed and run companies from the first patent through public listing or strategic sale.

Companies formed

12+

Formed more than a dozen companies based on novel platform technologies.

Exits

IPOs + sales

Taken many of our companies public or through strategic sale, investing and raising hundreds of millions of dollars from inception through exit.

Leadership

Chair + CEO

Served as chairman or chief executive officer of more than a dozen portfolio companies from inception through later rounds of financing.

[ Hands on ]

Builders, not bystanders.

We actively manage each new venture we form and serve as its scrappy, get-it-done management team, before scaling with a purpose-built team.

[ 02 ] Leadership

Meet the builders.

Physicians, scientists and operators who serve as each new company's first management team.

Jeff Wolf

01Managing Director

Founded Seed One in 1997 and has started more than a dozen companies, from Avigen to Scorpius.

Jeff has started more than a dozen companies based upon breakthrough research and technology. Jeff was formerly managing director at The Castle Group, a New York based venture firm focused on starting new companies based on breakthrough technologies. Jeff founded Seed One in 1997 to focus on identifying and acquiring cutting-edge technologies and systematically forming and running early-stage, high-growth companies based on these breakthroughs.

Since founding Seed One, Jeff has created and run over a dozen high-growth biomedical companies including Avigen, a San Francisco-based gene therapy company; TyRx, a Princeton-based firm focused on the development of bio-compatible polymers; Elusys Therapeutics, a New Jersey company focused on the development of a novel technology to remove blood-borne pathogens; Sensatex, a Maryland company focused on the development of novel medical diagnostic systems; Heat Biologics, a Research Triangle-based company focused on the development of novel therapeutics to prime the immune system against a variety of disorders; and Scorpius BioManufacturing, a San Antonio based biologic CDMO.

Jeff received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law and his B.A. from the University of Chicago, where he graduated with honors in Economics.

Scott Wolf, M.D.

02Managing Director

Physician and inventor. Founded ZELTIQ, Primaeva and Aerin Medical.

Scott is a prolific medical device entrepreneur, inventor and venture capitalist. Over the past 20 years, Scott founded numerous successful medical device companies across a broad range of therapeutic areas.

Scott was a partner with Prospect Venture Partners and Frazier Healthcare Ventures, both leading life science venture capital firms.

Scott founded and served as CEO of ZELTIQ, which markets the first effective non-invasive method of body sculpting and cellulite therapy, and Primaeva, acquired by Syneron Medical (ELOS), which developed and is marketing a device for office-based aesthetic procedures. ZELTIQ completed its initial public offering in 2011. Scott's latest start-up is Aerin Medical, a company he formed to commercialize his newly invented device and procedure to improve nasal breathing.

Scott was also a founder of Cardiac Dimensions and EndoGastric Solutions, two successful medical device companies.

Scott's companies are funded by the leading life science corporations and venture capital firms, including Venrock, ATV, Interwest, Johnson & Johnson Development Corporation, Medtronic, Mitsubishi UFJ Capital, MPM and Frazier Healthcare Ventures.

Scott received his M.D. from George Washington University and his B.A. from the University of Pennsylvania.

Matthew M. Seavey, Ph.D.

03Director

Immunologist with over a decade in preclinical drug development.

As Vice President of Research and Business Development, Matthew Seavey holds over a decade of preclinical drug development experience. Originally trained as an immunologist, Dr. Seavey is an expert in early drug development and has been involved in the development of different drug modalities (biologics, small molecules, cellular therapeutics, vaccines) across multiple therapeutic areas, including GI, CNS, immuno-oncology, respiratory, inflammation and cardio-metabolics.

He has held former positions as Drug Discovery Team Leader at Cephalon, Global Pharmacology Project Leader at Teva Pharmaceuticals, and Oncology Program Director at United Therapeutics. Dr. Seavey is a co-inventor on several patents and has contributed to the intellectual property base of Advaxis and the founding of Oncoceutics. Most recently, Dr. Seavey served as Director of Preclinical Pharmacology for CinRx Pharma and founding partner of BioPoint Consulting, LLC.

Dr. Seavey holds a B.S. in Microbiology from the University of Vermont, an M.Sc. and Ph.D. in Immunology from the University of Rochester, and an M.B.A. from West Chester University.

Ryan Kane

04Director

Leads government affairs and business development at Elusys.

Ryan Kane is the Vice President of Government Affairs and Business Development for Elusys, where he oversees federal and state government relations, public affairs initiatives, communications, and business development opportunities.

Ryan also served as President of RK Strategies, Inc., a public affairs and political consultancy with clients spanning publicly-traded pharmaceutical, energy, and technology sectors, and a founding partner of RKS Capital Holdings, LLC, a boutique investment group.

Ryan has advised U.S. Senators, Governors, and a half-dozen members of the U.S. House of Representatives.

[ 03 ] Contact · Work with proven builders

Our team is ready to partner with visionary founders who are developing breakthrough technologies.

Get in touchSee what we've built

Build with us.

[ Team ] 01 / 04

[ 06 ] Contact

Ready to forge the future together?

If you have breakthrough technology that could reshape an industry, we want to hear from you.

I am
Please add your first name.
Please add your last name.
Please add a valid email address.
Please add your company or organization.

We only use these details to reply to you.